Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
PanGenomic Health Inc - Vancouver, Canada-based precision health company - Enters a non-binding letter of intent on Tuesday with Interactive Health Inc, where it will license IHI’s CyberPatient AI medical education platform. The licensing is for the exclusive use in the consumer, public health, and complementary and alternative medicine sectors, the firm says. Says it will buy the CyberPatient licence from IHI for an aggregate purchase price of C$5.3 million, or about £3.2 million.
Chief Executive Officer Maryam Marissen says: ‘We are thrilled to welcome the CyberPatient AI Platform to PanGenomic. Its digital twin technology will enhance our Nara self-care platform, providing a personalized, visual health journey for our users. It is an important step in empowering individuals and their natural healthcare practitioners with cutting-edge tools to better understand and utilize multi-dimensional health data, AI insights, and genomic data, contributing to our mission of improving health care through advanced technology.’
Current stock price: C$0.06
12-month change: down 78%
Copyright 2023 Alliance News Ltd. All Rights Reserved.